Glucose dehydrogenase mutant and application thereof in NMNH synthesis
By mutation of glucose dehydrogenase, an efficient mutant enzyme is formed, and the efficient transformation of NMN into NMNH is achieved in one step, which solves the complex steps and contamination problems in the existing NMNH synthesis process, and achieves efficient and simplified NMNH production .
Patent Information
- Application Number
- CN202310628943.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
There are problems of chemical contamination, complicated enzymatic steps and many enzyme components in the existing NMNH synthesis process, making it difficult to achieve efficient and simplified NMN to NMNH conversion.
By mutating glucose dehydrogenase, a mutant can mutation or insertion at specific sites on the amino acid sequence, enhancing the binding force of NMN and protein, thereby achieving efficient transformation of NMN catalyzed into NMNH in one step, using recombination The vector and genetically engineered bacteria are expressed and purified to form an efficient enzyme preparation method.
High conversion rate and rapid catalysis of NMN to NMNH are achieved, reducing steps and cofactor use, reducing costs, and suitable for industrial production.
Smart Images

Figure CN119060974A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, in particular to a glucose dehydrogenase mutant and application thereof in NMNH synthesis. Background Art
[0002] Nicotinamide adenine dinucleotide (NAD + ), is an important coenzyme in the human body's redox reaction, participates in important metabolic pathways such as glycolysis, tricarboxylic acid cycle, and fat β-oxidation, and is an essential substance in organisms. NAD + It is a substrate for enzymes such as the DNA repair enzyme PARP, deacetylase and longevity protein Sirtuins, and plays an important role in slowing down aging. However, since it cannot be transported across the membrane, its level in the body can only be increased by supplementing its precursor substances. The common β-nicotinamide mononucleotide (NMN) on the market is an effective NAD + Precursor supplements. The latest research shows (Liu J. Proteome Res. 2021, 20, 2596-2606) that the reduced form of NMN (NMNH) can increase NAD more effectively than NMN in vivo or in vitro + level, so the NMNH market prospects are good.
[0003] NMNH can be synthesized by chemical or enzymatic methods. Patent CN202080007810.3 uses a chemical method to reduce NMN to produce NMNH by using thiourea dioxide (TDO) as a reducing agent. Ammonia water is used in the reaction process, and acetonitrile is required in the purification process, which causes certain pollution. Enzymatic synthesis is more environmentally friendly, but since there is no natural enzyme that directly catalyzes NMN to produce NMNH, the seemingly simple one-step reduction reaction actually requires three steps of catalysis to complete, see Figure 1 : The first step is to synthesize NAD from NMN under the catalysis of enzyme (NMNAT, EC2.7.7.1) + , adenosine triphosphate (ATP) is needed to provide the molecular structure skeleton and energy supply; the second step is to use NAD + Reduced to reduced coenzyme I (NADH), there are many types of enzymes that catalyze this step, most of which are dehydrogenases, such as lactate dehydrogenase (LDH), alcohol dehydrogenase (ADH), glycerol dehydrogenase (GlyDH), malate dehydrogenase (MDH) and glucose dehydrogenase (GDH); the third step, in NAD + Under the catalysis of diphosphatase (NudC, EC 3.6.1.22), NADH is hydrolyzed into NMNH and adenylate (AMP). The enzymatic synthesis process is green and environmentally friendly, and the product purity is high, but it is urgent to solve the technical problems of using many enzyme components and complicated steps. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a glucose dehydrogenase mutant and its application in the synthesis of NMNH. As a high-performance enzyme element, it can catalyze NMN into NMNH in one step with high yield and fast speed.
[0005] The technical problem to be solved by the present invention is achieved through the following technical solutions:
[0006] One object of the present application is to provide a glucose dehydrogenase mutant, wherein the mutant is mutated based on the amino acid sequence of the wild-type glucose dehydrogenase (GDH) as shown in SEQ ID No.1, and the mutation is an amino acid sequence in which one or more amino acids are substituted and / or added to the amino acid sequence shown in SEQ ID No.1.
[0007] Preferably, the mutation sites of the amino acid sequence shown in SEQ ID No. 1 include at least one of the following: position 16, position 17, position 18, position 39, position 65, position 93, position 95, position 193, position 195, position 196, and position 198.
[0008] Preferably, the mutant is S16T, T17N or T17Q, G18D, R39K, D65A or D65G, A93E or A93D, M95Y or M95F, T193S or T193R or T193K, I195R or I195K, N196Q, E198Q or E198N, any single point mutation or any combination mutation on the amino acid sequence shown in SEQ ID No.1.
[0009] Preferably, the mutant is formed by inserting an amino acid between positions 38 and 39 of the amino acid sequence shown in SEQ ID No. 1 to form Y38YHG or Y38YWG, or inserting an amino acid between positions 93 and 94 to form A93AGE.
[0010] The above site modifications reduce the size of the protein's active pocket and strengthen the binding force between NMN and the amino acid residues of the protein.
[0011] Another object of the present application is to provide a recombinant vector, wherein the protein expressed by the recombinant vector comprises a glucose dehydrogenase mutant.
[0012] Another object of the present application is to provide a recombinant genetically engineered bacterium comprising a recombinant vector.
[0013] Preferably, the host cell of the recombinant genetically engineered bacteria is Escherichia coli.
[0014] Another object of the present application is to provide a method for preparing a glucose dehydrogenase mutant, comprising the following steps:
[0015] (1) using a recombinant genetically engineered bacterium containing a glucose dehydrogenase mutant as a production strain, wherein the strain uses pET22b(+) as an expression vector and Escherichia coli as a host cell to obtain an expression strain;
[0016] (2) The expression strain was inoculated into a shake flask for cultivation in LB medium. 1 mM isopropyl-β-D-thiogalactoside (IPTG) was added to induce the culture until the logarithmic growth phase. The cells were collected after 5 hours.
[0017] (3) The harvested bacteria are disrupted by ultrasound, and the supernatant is collected by centrifugation to obtain the expressed enzyme;
[0018] (4) Purifying the expressed enzyme to obtain the catalytic enzyme, i.e., the glucose dehydrogenase mutant.
[0019] Another object of the present application is to provide an application of a glucose dehydrogenase mutant in NMNH synthesis.
[0020] The glucose dehydrogenase mutant can catalyze NMN to generate NMNH in one step, the reaction system contains glucose and magnesium ions, the pH value is neutral or neutral to alkaline (6.5-9.0), and the temperature is 30-45°C.
[0021] Preferably, the application is:
[0022] 500 mM NMN, 500 mM glucose, 20 mM magnesium chloride and 20 mM Tris were added to the reaction system, the pH value was adjusted to 7.5, and the temperature was controlled at 35°C; 500 U of mutant enzyme was added to react and produce NMNH.
[0023] The above technical solution of the present invention has the following beneficial effects:
[0024] The glucose dehydrogenase mutant modified by the technical solution of the present invention can directly catalyze NMN to generate NMNH, replacing the three-step catalytic reaction, with high conversion rate and fast catalytic speed, without the need to add other cofactors such as ATP, saving raw materials and greatly reducing costs. In addition, the enzyme catalytic conditions are mild, and both free enzyme and immobilized enzyme are suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate embodiments of the invention and, together with the description, serve to explain the principles of the invention.
[0026] Figure 1 The NMNH reaction route of the prior art.
[0027] Figure 2 This is a schematic diagram of the tetrameric structure of wild-type glucose dehydrogenase in Example 1.
[0028] Figure 3 NAD of Example 1 + Schematic diagram of the active center after docking with the wild-type protein.
[0029] Figure 4 The SDS-PAGE electrophoresis diagram of the mutant protein expression in Example 2.
[0030] Figure 5 This is the HPLC chart for the detection of NMNH and NMN in Example 3.
[0031] Figure 6 Schematic diagram of the active center after docking of NMN and mutant protein in Example 4. DETAILED DESCRIPTION
[0032] Various exemplary embodiments of the present invention will now be described in detail with reference to the accompanying drawings. It should be noted that the relative arrangement of components and steps, numerical expressions and numerical values set forth in these embodiments do not limit the scope of the present invention unless otherwise specifically stated.
[0033] Example 1 Molecular dynamics simulation and structural analysis
[0034] NMN molecule and NAD + The molecules have certain structural similarities. NMN molecules are more similar to NAD + The molecule lacks an AMP structural region and can utilize catalytic NAD + The enzymes that are reduced to NADH are structurally modified. The enzyme library is searched to obtain lactate dehydrogenase (LDH), alcohol dehydrogenase (ADH), glycerol dehydrogenase (GlyDH), malate dehydrogenase (MDH) and glucose dehydrogenase (GDH). After preliminary analysis and activity experiments, Priestia megaterium glucose dehydrogenase (GDH, EC1.1.1.47) was selected for protein modification, and the protein sequence is shown in SEQ ID No.1.
[0035] The molecular dynamics simulation steps are as follows:
[0036] (I) The wild-type protein sequence (SEQ ID No. 1) was modeled using the Swiss-Model website, and the modeling template PDB ID: 1GCO. The parts that were not completed by automatic modeling were completed using Avogadro 1.2.0 software.
[0037] (ii) Use Gromacs2023 software to perform molecular dynamics simulation on the protein to restore its model to a relatively stable state close to the natural environment. During the above dynamics simulation process, the protein was processed using the Amber03 force field. The protein model was placed in a cubic box, and the minimum distance between the protein and the box was 1.0 nanometers. The box was filled with the water molecule model of TIP3P, and the protein solution system was made electrically neutral by adding sodium ions. The system was energy minimized using the steepest descent method, and then the system temperature was raised from 0K to 310K to perform isothermal and isochoric equilibrium (constant particle number, volume and temperature balance, NVT) and isothermal and isobaric equilibrium (constant particle number, pressure and temperature balance, NPT). Next, under the NPT system, a 30 nanosecond dynamics simulation was performed with a simulation step size of 2 femtoseconds, and the data of the system was saved every 10 nanoseconds.
[0038] (III) Molecular ligands glucose and NAD + , NMN, NADH and NMNH were modeled using avogardro1.2.0 software, and processed using AmberTools19 software and the corresponding BCC force field.
[0039] (IV) Use the model after structural stabilization to perform kinetic simulation of protein binding to ligand. During the above kinetic simulation, the protein uses the Amber03 force field. During the kinetic simulation, the protein and small molecule ligand models are placed in a cubic box, and the minimum distance between the protein and the box is 1.0 nanometers. Fill the box with the water molecule model of TIP3P, and make the solution system containing the protein and ligand electrically neutral by adding sodium ions. Use the steepest descent method to minimize the energy of the system, then increase the system temperature from 0K to 310K, and perform isothermal, isochoric equilibrium and isothermal, isobaric equilibrium. Next, in the system after isothermal and isobaric equilibrium, a 30 nanosecond kinetic simulation is performed, the simulation step size is 1 femtosecond, and the data of the system is saved every 5 nanoseconds.
[0040] The structural analysis of the simulated protein and ligand docking model is as follows:
[0041] The protein is a homotetrameric structure, see Figure 2 Each monomer subunit is composed of 261 amino acids. The active center pocket is formed by the α-helix and random coil structure. + Molecules are embedded in it, see Figure 3 .NAD +The NMN region of the molecule is hydrogen-bonded to sites such as I191 of the protein, and the AMP region is hydrogen-bonded to sites such as D65 of the protein. In order for the enzyme to catalyze NMN as a substrate, the active pocket structure needs to be modified to modify the substrate specificity of the enzyme. After structural analysis, the protein S16, T17, G18, R39, D65, A93, M95, T193, I195, N196 and E198 sites were selected for site-directed mutation or amino acids were inserted between Y38 and R39 and between A93 and G94 in the free rotation region. Among them, the modification of D65 is to reduce the binding force between the AMP part and the protein, and the modification of all other sites is to change the size of the active pocket and the binding force between the ligand and the amino acid residues of the protein.
[0042] The mutant proteins and ligands were subjected to molecular dynamics simulation using the above-mentioned molecular dynamics simulation steps, and the following mutant sets were screened out: S16T, T17N, T17Q, G18D, R39K, D65A, D65G, A93E, A93D, M95Y, M95F, T193S, T193R, T193K, I195R, I195K, N196Q, E198Q and E198N, as well as insertion of HG or WG between Y38 and R39 (Y38YHG or Y38YWG), and insertion of GE between A93 and G94 (A93AGE).
[0043] Example 2 Single point mutant protein upstream construction and protein expression
[0044] (1) Construction of expression vector:
[0045] The wild-type glucose dehydrogenase DNA sequence of Priestia megaterium is shown in SEQ ID No. 2 and connected to the pET22b(+) vector and named pET22b-pmgdh.
[0046] (2) Primer sequences of mutants:
[0047] Primers were designed for the mutation sites in Example 1, and plasmid PCR was performed using pET22b-pmgdh as a template. Taking the S16T single point mutant as an example, the sense primer S16T-F sequence was: 5'-CAGGTTCAACCACCGGTTTAGGAAAAGCAATG-3'; the antisense primer S16T-R sequence was: 5'-AACCGGTGGTTGAACCTGTTATGACAACTAC-3'.
[0048] Taking the WG mutant inserted after Y38 as an example, the sequence of the sense primer Y38+WG-F is: 5'-GTGAACTATTGGGGTCGTTCGAAAGAAGAAGAAGC-3'; the sequence of the antisense primer Y38+WG-R is: 5'-CGAACGACCCCAATAGTTCACAACTACTTTAGCT-3'.
[0049] PCR conditions were: denaturation at 95°C for 50 seconds, annealing at 58°C for 30 seconds, extension at 72°C for 10 minutes, 30 cycles, and 72°C for 20 minutes. The PCR product was purified, digested with DpnI, and directly transformed into E. coli DH5α competent cells to obtain transformants. The plasmid was extracted, sequenced, and verified to be correct, indicating that the site modification was successful. Other sites were mutated in the same way.
[0050] (3) Expression
[0051] The constructed plasmid was transformed into Escherichia coli using the calcium chloride method to obtain the corresponding BL21 (DE3) expression bacteria. The specific implementation steps are conventional molecular biology methods and will not be repeated here.
[0052] The expression bacteria were inoculated into a shake flask for culture in LB medium. When the culture reached the logarithmic growth phase, 1 mM isopropyl-β-D-thiogalactoside was added for induction. The bacteria were collected after 5 hours. Figure 4 This is a polyacrylamide protein electrophoresis diagram. Lane 1 is a protein marker 14-100kDa (commercially available); Lane 2 is a wild-type protein, with a size of about 29kDa; Lanes 3-5 list three mutant proteins, namely T193R, I195R and A93AGE, all with a size of about 29kDa. Other mutant proteins are not listed.
[0053] Example 3 Mutation site screening
[0054] The above-harvested bacteria were ultrasonically disrupted, and the supernatant was collected by centrifugation to obtain a crude enzyme solution, which was added to a standard reaction system for reaction to determine the activity of protein-generated NMNH. The standard reaction system contained 20mM NMN, 20mM glucose, 20mM ATP, 20mM magnesium chloride, and 50mM Tris, and the pH value was adjusted to 7.0. 20mg / ml crude enzyme solution was added for reaction, and the temperature was set to 35°C.
[0055] The amount of NMNH generated was detected by high performance liquid chromatography, the mobile phase was a buffer solution containing 15 mM KH2PO4, 5 mM tetrabutylammonium hydroxide and 10% methanol, the chromatographic column was a Kromasil C18 column, the detection flow rate was 1 ml / min, the detection wavelength was 230 nm, the detection temperature was 30 °C, see Figure 5 , the retention times of NMNH and NMN were 18.3 and 2.5 min, respectively.
[0056] The activities of the wild type and each single-point mutant in generating NMNH are shown in Table 1. Modification of the A93, M95, T193, I195 and N196 sites can significantly enhance the activity of the enzyme in catalyzing the generation of NMNH.
[0057] Table 1. List of single point mutant activities
[0058]
[0059]
[0060] According to the catalytic activity data of single-point mutants, A93E, A93D, M95Y, M95F, T193S, T193R, T193K, I195R, I195K, N196Q and A93AGE are the most effective mutation sites.
[0061] Continue to select suitable sites for combined mutation, perform kinetic simulation analysis of protein structure according to the method described in Example 1, and then perform molecular biological transformation to express protein. It was confirmed by protein activity screening that although some single-point mutant enzymes have no activity, after combined mutation, the enzyme activity can be further improved. The following are combined mutants with higher activity, see Table 2.
[0062] Table 2. List of combined mutant activities
[0063]
[0064]
[0065] Figure 6 is a schematic diagram of the active pocket of mutant SEQ ID No.10, and Figure 3 Compared with the wild-type protein, it can be seen that the active pocket of the mutated protein is significantly reduced, and the NMN molecule can effectively bind to the protein.
[0066] Example 4 Screening of industrial enzymes
[0067] The mutant enzyme strains in Table 2 of Example 3 were inoculated into shake flasks for culture, and the culture medium was LB culture medium. After growing to the logarithmic growth phase, they were connected to a fermenter for culture, using an optimized M9 culture medium. After the strains grew to the logarithmic growth phase, 1mM isopropyl-β-D-thiogalactoside (IPTG) was added for induction, and the cells were collected after 5 hours. The above-mentioned harvested cells were ultrasonically broken and the supernatant was collected by centrifugation. Then, the expressed enzyme was purified using ammonium sulfate precipitation, anion exchange, G25 desalting and other steps to obtain a purified catalytic enzyme.
[0068] The enzymatic reaction conditions of each catalytic enzyme in the experiment are shown in Table 3.
[0069] Table 3. List of combined mutant activities
[0070] sequence Reaction pH Reaction temperature (℃) Enzyme half-life (37℃) SEQ ID No.3 6.5-8.5 30-45 16 hours SEQ ID No.4 6.5-8.5 30-45 16 hours SEQ ID No.5 6.5-8.5 30-45 12 hours SEQ ID No.6 6.5-8.5 30-45 18 hours SEQ ID No.7 6.5-8.5 30-45 18 hours SEQ ID No.8 6.5-9.0 30-45 18 hours SEQ ID No.9 6.5-8.5 30-45 12 hours SEQ ID No.10 6.5-8.5 30-45 18 hours
[0071] It can be seen that the mutant protein can be used as a catalytic reaction under neutral to alkaline pH and mild temperature conditions. The enzyme activity is relatively stable, and its half-life period can be further extended if an immobilized enzyme is used.
[0072] Example 5 Experiment of synthesizing NMNH using mutant enzyme
[0073] Add 500mM NMN, 500mM glucose, 20mM magnesium chloride and 20mM Tris to the reaction system, adjust the pH to 7.5, and control the temperature at 35°C. Add the purified mutant enzyme SEQ ID No.10 to the reaction system, with an addition amount of 500U (the amount of enzyme required to convert 1 micromole of substrate within 1 minute is 1U). During the reaction, add acid and alkali to adjust the pH to 7.5. The reaction lasts for about 6 hours, and the maximum amount of NMNH generated by HPLC high-pressure liquid phase detection can reach 460mM.
[0074] It can be seen that the mutant protein can use NMN as a substrate to generate NMNH with a high conversion rate, and is suitable for industrial production.
[0075] Comparative Example 1 Experiment of synthesizing NMNH using wild enzymes
[0076] 500mM NMN, 500mM glucose, 20mM magnesium chloride and 20mM Tris were added to the reaction system, the pH was adjusted to 7.5, and the temperature was controlled at 35°C. The purified wild enzyme was added to the reaction system in an amount equal to the mass of the mutant enzyme in Example 5. During the reaction, acid and alkali were added to adjust the pH to 7.5. After 6 hours of reaction, NMNH was not generated by HPLC high pressure liquid phase detection.
[0077] Although the present invention has been disclosed as above by the embodiments, it is not intended to limit the present invention. Any person skilled in the art may make various choices and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention is limited by the claims and their equivalents.
Claims
1. A glucose dehydrogenase mutant, characterized in that: The mutant is mutated based on the amino acid sequence of wild-type glucose dehydrogenase (GDH) as shown in SEQ ID No. 1, and the mutation is an amino acid sequence in which one or more amino acids are substituted and / or added to the amino acid sequence shown in SEQ ID No.
1.
2. The glucose dehydrogenase mutant according to claim 1, characterized in that The mutation sites of the amino acid sequence shown in SEQ ID No. 1 include at least one of the following: position 16, position 17, position 18, position 39, position 65, position 93, position 95, position 193, position 195, position 196, and position 198.
3. The glucose dehydrogenase mutant according to claim 1, characterized in that The mutant is S16T, T17N or T17Q, G18D, R39K, D65A or D65G, A93E or A93D, M95Y or M95F, T193S or T193R or T193K, I195R or I195K, N196Q, E198Q or E198N, any single point mutation or any combination mutation in the amino acid sequence shown in SEQ ID No.
1.
4. The glucose dehydrogenase mutant according to claim 1, characterized in that The mutant is formed by inserting an amino acid between positions 38 and 39 of the amino acid sequence shown in SEQ ID No. 1 to form Y38YHG or Y38YWG, or inserting an amino acid between positions 93 and 94 to form A93AGE.
5. A recombinant vector, characterized in that: The recombinant vector comprises the glucose dehydrogenase mutant according to any one of claims 1-4.
6. A recombinant genetically engineered bacterium, characterized in that: The recombinant genetically engineered bacteria comprises the recombinant vector according to claim 5.
7. The method for preparing a glucose dehydrogenase mutant according to claim 1, characterized in that: The following steps are involved: (1) A recombinant genetically engineered bacterium containing a mutant of glucose dehydrogenase according to any one of claims 1 to 4 is used as a production strain, wherein the strain uses pET22b(+) as an expression vector and Escherichia coli as a host cell to obtain an expression strain; (2) The expression strain was inoculated into a shake flask for cultivation in LB medium. 1 mM isopropyl-β-D-thiogalactoside (IPTG) was added to induce the culture until the logarithmic growth phase. The cells were collected after 5 hours. (3) The harvested bacteria are disrupted by ultrasound, and the supernatant is collected by centrifugation to obtain the expressed enzyme; (4) Purifying the expressed enzyme to obtain the catalytic enzyme, i.e., the glucose dehydrogenase mutant.
8. Use of the glucose dehydrogenase mutant according to any one of claims 1 to 4 in NMNH synthesis.
9. The use according to claim 8, characterized in that: The glucose dehydrogenase mutant can catalyze NMN to generate NMNH in one step, and the reaction system contains glucose and magnesium ions, a pH value of 6.5-9.0, and a temperature of 30-45°C.
10. The use according to claim 9, characterized in that: The application is: Add 500 mM NMN, 500 mM glucose, 20 mM magnesium chloride, and 20 mM Tris to the reaction system, adjust the pH to 7.5, and control the temperature at 35 °C; 500 U of mutant enzyme was added, the pH value was adjusted to 7.5, and the reaction produced NMNH.
Citation Information
Patent Citations
Synthetic method for nmn derivative and medical applications of nmn and its derivative
CN113490676A
Cited By
Phosphate dehydrogenase mutant, recombinant vector, recombinant genetically engineered bacterium and application thereof, and method for synthesizing reduced beta-nicotinamide mononucleotide
CN121628856A
